Edward M. Messing, M.D.

See information for Patients. Viewing information for Researchers.

Dr. Messing is an internationally renowned expert in all facets of urologic oncology, both as a clinician/surgeon, and as a clinical, translational and basic researcher.

His research contributions have ranged from enhancing our knowledge about the basic molecular biology and genetics of development and progression of cancers of the bladder, prostate and kidney, and bringing these studies to fruition for the detection, prevention and treatment of these diseases. He has also designed and conducted landmark phase III clinical trials for each of these cancers and has carried out the first screening trial for bladder cancer in a general population. Important work has included defining the roles of epidermal growth factor (EGF) and its cell surface receptor in urothelial carcinogenesis and progression, investigating polyamine synthesis inhibition as a means to prevent bladder and prostate cancers, in large phase III clinical trials studying DFMO's ability to prevent bladder cancer's recurrence, the timing of androgen deprivation therapy (ADT) in treating regionally advanced completely resected prostate cancer, and the effectiveness of adjuvant alpha interferon for completely resected, locally extensive, renal cell carcinoma. He has also contributed importantly to trials testing various forms of intravesical therapy for high risk, non-muscle invading bladder cancer, and the value of radiation therapy after prostatectomy for stage pT3 prostate cancer. He has demonstrated the feasibility of screening for bladder cancer (using hematuria reagent strips) and has worked on the development and testing of several molecular markers for the detection of bladder cancer.

Much of the above mentioned work continues, but currently he is also investigating gender disparities in bladder cancer's incidence and outcome.

These efforts have ranged from investigations using large, national data bases, to molecular studies in cells and transgenic animal models. Additionally, he along with his basic science collaborators are investigating the preventative and therapeutic roles of nuclear transcription factors, vitamins and related molecules in prevention and treatment of prostate and bladder cancer. Furthermore, his clinical trial work continues as the study coordinator (PI) of a large phase III clinical trial of immediate post TURBT intravesical instillation therapy for prevention of recurrence of low risk bladder cancer.

Current Appointments

• Chairman - Department of Urology (SMD)
• Winfield W. Scott Chair in Urology - Department of Urology (SMD)
• Professor - Department of Urology (SMD)
• Professor - Department of Pathology and Laboratory Medicine (SMD)
• Professor - Cancer Center (SMD)

Education
MD Medicine	New York Univ Sch Medicine	1972
BA Biology	University of Chicago	1968

Post-Doctoral Training & Residency
1972-1973 - Department of Surgery New York University - Bellevue Medical Center, New York, New York
1973-1974 - Surgical Residency New York University - Bellevue Medical Center, New York, New York
1974-1978 - Urology Residency Division of Urology, Stanford University, Stanford, California
1977-1978 - Chief Resident Division of Urology, Stanford University, Stanford, California
1980-1982 - Tumor Immunology and Urologic Oncology Departments of Microbiology and Immunology and Division of Urology, UCLA School of Medicine, Los Angeles, California

Board Certifications
The American Board of Urology

Recent Journal Articles
Showing the 5 most recent journal articles. (167 available)
Madeb R, Golijanin D, Noyes K, Fisher S, Stephenson JJ, Long SR, Knopf J, Lyman G, Messing EM. "Treatment of Superficial Bladder Cancer: Do physicians in the United States Practice Evidence Based Medicine? The use and economic implications of Intravesical Chemotherapy after Transurethral Resection of Bladder Tumors". Cancer (2009).
Messing EM, Madeb R, Feng CY, Stephenson L, Gilchrist KW, Young T, Gee J. "Do grade and stage at presentation predict outcome in patients with bladder cancer who survive their disease?". Journal of Clinical Oncology (2009).
Scosyrev E, Noyes K, Feng CY, Messing EMM. "Sex and racial differences in bladder cancer presentation and mortality in the United States". CANCER 1;115(1) (2009): 68-74.
Chen M, Hsu I, Wolfer A, Radovick S, Huang K, Yu S, Chang C, Messing EM, Yeh S. "Defects of prostate development and reproductive system in the estrogen receptor-alpha null male mice". Endocrinology 150(1) (2009): 251-259.
Messing EM, Madeb RM. "Long-term outcome of dip-stick testing for hematuria". World Journal of Urology 26(1) (2008): 19-24.